Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Radiation Injuries 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Neoplasms, Neuroepithelial 1Mucositis 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Head and Neck Neoplasms 1Exanthema 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 4Prednisone 3Lenalidomide 3fludarabine phosphate 2etoposide phosphate 2cobomarsen 2Whole-Body Irradiation 2Vorinostat 2Vincristine 2Stem Cell Transplantation 2Nivolumab 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Doxorubicin 2Bortezomib 2Alemtuzumab 2tazemetostat 1sargramostim 1romidepsin 1poly ICLC 1plerixafor 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1pegaspargase 1liposomal doxorubicin 1forodesine 1fludarabine 1duvelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, T-Cell × Fibroblast Growth Factor 7 × Clear all
NCT01746173 2023-01-30

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Terminated
5 enrolled 7 charts
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡